Future pre-clinical studies should address the interactions between PD-L1 and HER2 expression in DNA replication and/or its consequences in the STING-dependent immune response at the molecular level [19], as well as their impact in the tumor immune infiltrate. The gene discussed is ERBB2; the disease is neoplasm.